Progestin therapy is generally used for well‐differentiated endometrial cancer, and Ishikawa cell line was originally derived from a well‐differentiated adenocarcinoma of a 39‐year‐old woman in 1985,9 so we selected Ishikawa cell to developed progestin resistant cell line, because it is widely accepted that the presence of progesterone receptor (PR) is a prerequisite for progestin response.10 We firstly identified PGR correlated genes in EC and found the overlap genes with DEGs. The gene discussed is PGR; the disease is adenocarcinoma.